

2021

In Utero Exposure to Persistent Organic Pollutants and Childhood Lipid Levels

Maegan E. Boutot
University of Massachusetts Amherst

Brian W. Whitcomb
University of Massachusetts Amherst

Nadia Abdelouahab
Sherbrooke University

Andrea A. Baccarelli
Columbia University

Amélie Boivin
Sherbrooke University

See next page for additional authors

Follow this and additional works at: https://scholarworks.umass.edu/bioepi_faculty_pubs



Part of the [Biostatistics Commons](#), and the [Health Policy Commons](#)

Recommended Citation

Boutot, Maegan E.; Whitcomb, Brian W.; Abdelouahab, Nadia; Baccarelli, Andrea A.; Boivin, Amélie; Caku, Artuela; Gillet, Virginie; Martinez, Guillaume; Pasquier, Jean-Charles; Zhu, Jiping; Takser, Larissa; St-Cyr, Lindsay; and Suvorov, Alexander, "In Utero Exposure to Persistent Organic Pollutants and Childhood Lipid Levels" (2021). *Biostatistics and Epidemiology Faculty Publications Series*. 11(10), <https://doi.org/10.3390/metabo11100657>


This Article is brought to you for free and open access by the Biostatistics and Epidemiology at ScholarWorks@UMass Amherst. It has been accepted for inclusion in Biostatistics and Epidemiology Faculty Publications Series by an authorized administrator of ScholarWorks@UMass Amherst. For more information, please contact scholarworks@library.umass.edu.

Authors

Maegan E. Boutot, Brian W. Whitcomb, Nadia Abdelouahab, Andrea A. Baccarelli, Amélie Boivin, Artuela Caku, Virginie Gillet, Guillaume Martinez, Jean-Charles Pasquier, Jiping Zhu, Larissa Takser, Lindsay St-Cyr, and Alexander Suvorov

Article

In Utero Exposure to Persistent Organic Pollutants and Childhood Lipid Levels

Maegan E. Boutot¹, Brian W. Whitcomb¹, Nadia Abdelouahab², Andrea A. Baccarelli³, Amélie Boivin⁴, Artuela Caku⁵, Virginie Gillet⁴, Guillaume Martinez⁶, Jean-Charles Pasquier², Jiping Zhu⁷, Larissa Takser⁸, Lindsay St-Cyr⁴ and Alexander Suvorov^{1,9,*} 

- ¹ Department of Biostatistics and Epidemiology, School of Public Health and Health Sciences, University of Massachusetts Amherst, Amherst, MA 01003, USA; mboutot@umass.edu (M.E.B.); bwhitcomb@schoolph.umass.edu (B.W.W.)
- ² Department of Obstetrics and Gynecology, Faculty of Medicine and Health Sciences, Sherbrooke University, Sherbrooke, QC J1H 5N4, Canada; nadia.abdelouahab@usherbrooke.ca (N.A.); jean-charles.pasquier@USherbrooke.ca (J.-C.P.)
- ³ Department of Environmental Health Sciences, Mailman School of Public Health, Columbia University, New York, NY 10032, USA; andrea.baccarelli@columbia.edu
- ⁴ Department of Pediatrics, Faculty of Medicine and Health Sciences, Sherbrooke University, Sherbrooke, QC J1H 5N4, Canada; amelie.boivin@usherbrooke.ca (A.B.); virginie.gillet@usherbrooke.ca (V.G.); lindsay.st-cyr@usherbrooke.ca (L.S.-C.)
- ⁵ Department of Biochemistry and Functional Genomics, Faculty of Medicine and Health Sciences, Sherbrooke University, Sherbrooke, QC J1H 5N4, Canada; artuela.s.caku@usherbrooke.ca
- ⁶ Department of Chemistry, Faculty of Sciences, Sherbrooke, QC J1K 2R1, Canada; guillaume.martinez@usherbrooke.ca
- ⁷ Environmental Health Science and Research Bureau, Health Canada, Ottawa, ON K1A 0K9, Canada; jiping.zhu@canada.ca
- ⁸ Department of Pediatrics & Department of Psychiatry, Faculty of Medicine and Health Sciences, Sherbrooke University, Sherbrooke, QC J1H 5N4, Canada; larissa.takser@usherbrooke.ca
- ⁹ Department of Environmental Health Sciences, School of Public Health and Health Sciences, University of Massachusetts Amherst, Amherst, MA 01003, USA
- * Correspondence: asuvorov@umass.edu; Tel.: +1-413-545-3487



Citation: Boutot, M.E.; Whitcomb, B.W.; Abdelouahab, N.; Baccarelli, A.A.; Boivin, A.; Caku, A.; Gillet, V.; Martinez, G.; Pasquier, J.-C.; Zhu, J.; et al. In Utero Exposure to Persistent Organic Pollutants and Childhood Lipid Levels. *Metabolites* **2021**, *11*, 657. <https://doi.org/10.3390/metabo11100657>

Academic Editor: Wilfried Le Goff

Received: 3 September 2021

Accepted: 24 September 2021

Published: 28 September 2021

Publisher's Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

Abstract: Animal studies have shown that developmental exposures to polybrominated diphenyl ethers (PBDE) permanently affect blood/liver balance of lipids. No human study has evaluated associations between in utero exposures to persistent organic pollutants (POPs) and later life lipid metabolism. In this pilot, maternal plasma levels of PBDEs (BDE-47, BDE-99, BDE-100, and BDE-153) and polychlorinated biphenyls (PCB-138, PCB-153, and PCB-180) were determined at delivery in participants of GESTation and Environment (GESTE) cohort. Total cholesterol (TCh), triglycerides (TG), low- and high-density lipoproteins (LDL-C and HDL-C), total lipids (TL), and PBDEs were determined in serum of 147 children at ages 6–7. General linear regression was used to estimate the relationship between maternal POPs and child lipid levels with adjustment for potential confounders, and adjustment for childhood POPs. In utero BDE-99 was associated with lower childhood levels of TG ($p = 0.003$), and non-significantly with HDL-C ($p = 0.06$) and TL ($p = 0.07$). Maternal PCB-138 was associated with lower childhood levels of TG ($p = 0.04$), LDL-C ($p = 0.04$), and TL ($p = 0.02$). Our data indicate that in utero exposures to POPs may be associated with long lasting decrease in circulating lipids in children, suggesting increased lipid accumulation in the liver, a mechanism involved in NAFLD development, consistent with previously reported animal data.

Keywords: dyslipidemia; fetal programming; lipid metabolism; NAFLD; persistent organic pollutants

1. Introduction

Polybrominated diphenyl ethers (PBDEs) are related brominated organic chemicals used widely as flame-retardants in synthetic materials, including clothing. Concentrations

of PBDEs have increased in a broad range of environmental samples and human media over approximately 30 years [1]. Despite withdrawal from the US market by 2013, current human exposure to PBDEs remains close to their historical maximum in North America due to their presence in consumer products and other materials in households and other living locations. Some studies suggest that human PBDE burdens may even continue to increase because of the persistence of PBDEs in the environment [2]. Because of their lipophilicity and chemical stability [3,4] PBDEs accumulate in adipose tissue and are mobilized in pregnancy [5]. As a result, the developing fetus is exposed via cord blood [5]. These findings are supported by the fact that PBDEs are found in the majority of fetal samples in North America [6,7].

In the liver, there is an overlap between lipid metabolism and detoxification pathways of drugs and xenobiotics. For example, xenobiotic-inducible nuclear receptors regulate both xenobiotic metabolism and lipid homeostasis [8–18]. In addition, expression of hepatic enzymes involved in metabolism of xenobiotics and lipids differ significantly by sex [19–24]. In humans, 1249 sex-specific genes have been identified in the liver [22], and found to be enriched for lipid metabolism and cardiovascular disease among other biological categories. These data suggest induction of lipid metabolism pathways after chemical exposures and sexually dimorphic character of this response.

Concerningly, PBDEs exposure produce transient effects on lipid metabolism via reversible induction of liver nuclear receptors, constitutive androstane receptor (CAR) and pregnane X receptor (PXR) [25]. Recent rodent studies demonstrate however, that developmental exposures to PBDEs may result in permanent effects on lipid metabolism leading to dyslipidemia and a non-alcoholic fatty liver disease (NAFLD)-like phenotype [26,27]. The molecular basis of these programming events is not well understood but likely includes liver epigenome remodeling [28].

In this study, based on our results from animal studies [26,29], we hypothesized that in utero exposures to PBDEs would produce long lasting effects in liver metabolism of lipids in humans. To test this hypothesis, we evaluated the associations between maternal blood organohalogens at delivery and lipid profiles of children at 6–7 years of age in the prospective GESTation and Environment (GESTE) cohort.

2. Results

Our analysis of dyads with complete data on in utero exposure, age 6–7 childhood lipids, and covariates represents substantial dropout in this longitudinal study among women who provided blood samples and information at delivery. Comparisons of those included in analysis ($n = 147$, 25%) with those who excluded due to dropout ($n = 413$, 75%) identified small differences in age (29.3 vs. 28.4, $p = 0.04$) and BDE-153 (0.012 vs. 0.022, $p = 0.03$), but no differences were observed in other in utero chemical concentrations or BMI. In addition, at baseline, only a subset of women chose to participate in follow-up visits, further suggesting randomness to dropout and low probability of selection bias as a result.

Sample summary statistics are presented in Tables 1 and 2. Table 1 displays participant-pair ($n = 147$) characteristics and serum levels for selected metals by tertiles of child's total lipid levels. Maternal age significantly ($p < 0.05$) varied by total lipid levels. Manganese levels at delivery also varied significantly by total lipids; however, this variable was not associated with any of the individual PCBs, PBDEs, or the PCB or PBDE summation variables (range of t-test p -values: 0.53–0.996, data not shown). Based on bivariate analyses, maternal age at pregnancy and post-pregnancy BMI were included as potential confounders in adjusted, multivariable models.

Table 1. Participant-Pairs Characteristics by Total Lipid Tertiles (mmol/L). GESTE Cohort.

	Tertile 1, n = 51 (Lower-Upper) ⁺		Tertile 2, n = 45 (Lower-Upper) ⁺		Tertile 3, n = 51 (Lower-Upper) ⁺		p [#]
	4.05	0.35	4.72	0.15	5.55	0.46	
	Mean *	(SD)	Mean *	(SD)	Mean *	(SD)	
Maternal age (years) at pregnancy	30.3	(3.9)	30.0	(4.4)	27.8	(4.9)	0.009
Maternal BMI after delivery	26.7	(4.5)	26.6	(5.3)	27.4	(6.2)	0.76
Child BMI at age 6–7 years	15.8	(1.4)	15.9	(1.5)	15.9	(1.9)	0.95
PCB Sum (ng/mL)	0.090	(3.34)	0.086	(2.71)	0.066	(4.63)	0.43
BDE Sum (ng/mL)	0.135	(3.56)	0.123	(3.66)	0.155	(3.93)	0.68
Triglycerides (mmol/L)	0.697	(1.39)	0.794	(1.36)	1.393	(1.43)	<0.0001
Maternal serum lead levels at delivery (umol/L)	0.037	(1.46)	0.037	(1.62)	0.041	(1.71)	0.35
Maternal serum manganese levels at delivery (nmol/L)	247.0	(1.27)	253.3	(1.35)	282.0	(1.29)	0.03
Maternal serum cadmium levels at delivery (nmol/L)	2.008	(2.09)	1.716	(1.65)	2.117	(2.02)	0.29
Maternal serum mercury levels at delivery (µg/L)	2.585	(2.00)	2.740	(1.67)	2.351	(2.04)	0.51
Child serum lead levels at 6–7 years (umol/L)	0.033	(1.58)	0.037	(1.52)	0.035	(1.53)	0.54
Child serum manganese levels at 6–7 years (nmol/L)	172.2	(1.32)	185.6	(1.30)	178.8	(1.27)	0.37
Child serum cadmium levels at 6–7 years (nmol/L)	0.800	(1.41)	0.795	(1.31)	0.803	(1.27)	0.99
Child serum mercury levels at 6–7 years (µg/L)	1.569	(1.83)	1.474	(1.88)	1.512	(1.84)	0.88
% Female child	35.3%		48.9%		49.0%		0.28
% Reported smoking during pregnancy ^a	6.0%		0.0%		7.8%		0.18
% Reported alcohol use during pregnancy ^a	30.0%		25.0%		25.5%		0.83
% Vaginal delivery ^a	82.4%		75.6%		84.3%		0.53
Maternal educational level							
Primary	0.0%		0.0%		2.0%		
Secondary	9.8%		8.9%		19.6%		
College	19.6%		24.4%		29.4%		0.42
University	35.3%		42.2%		27.5%		
Other	31.3%		22.2%		21.6%		
Missing	3.9%		2.2%		0.0%		

Abbreviations: SD-standard deviation, BMI-body mass index (kilograms/(meters²)), PCB-Polychlorinated biphenyl, BDE-Decabromodiphenyl ether. ⁺ Lower and upper bounds for the tertiles of total lipids, measured by Phillip's Method, in mmol/L. * Mean and SD represent geometric mean and geometric SD. [#] p-Value from one-way ANOVA for all linear characteristics. For categorical characteristics, Chi-Squared tests were used except for smoking and maternal education level, which required Fisher's Test. ^a. These groups had 2 participants with missing information.

Table 2. Distributions of organohalogenes (ng/mL) among mothers within GESTE cohort.

	% below LOC	Minimum	25% Q1	50% Median	75% Q3	Maximum	Q3 ÷ Q1
BDE 47	0%	0.00035	0.020	0.05	0.11	1.05	5.6
BDE 99	13%	0.00005	0.004	0.02	0.06	0.64	14.1
BDE 100	12%	0.00005	0.010	0.02	0.06	0.43	5.8
BDE 153	16%	0.00005	0.008	0.03	0.06	0.87	8.3
Sum BDEs	–	0.00241	0.064	0.14	0.34	2.49	5.3
PCB 138	20%	0.00001	0.002	0.02	0.04	0.27	18.1
PCB 153	5%	0.00001	0.024	0.05	0.07	0.41	3.0
PCB 180	10%	0.00001	0.009	0.03	0.05	0.26	4.8
Sum PCBs	–	0.00003	0.039	0.09	0.16	0.91	4.1
Sum of All Organohalogenes	–	0.00244	0.14	0.27	0.55	2.64	3.9

Total number of participants included in analyses was 147. Abbreviations: PCB-Polychlorinated biphenyl, BDE-Decabromodiphenyl ether.

Overall, most POPs were not strongly associated with childhood lipid levels in simple or adjusted models; however, PCB-138 and BDE-99 were moderately ($p < 0.10$) or significantly ($p < 0.05$) associated with multiple lipid measurements (Table 3). PCB-138 was associated significantly with TG ($p = 0.04$), LDL-C ($p = 0.04$) and TL ($p = 0.02$) and associated moderately with TCh ($p = 0.09$) and HDL-C ($p = 0.07$). BDE-99 was significantly associated with TG ($p = 0.003$) and moderately associated with HDL-C ($p = 0.06$) and TL ($p = 0.07$) (Table 3). Additionally, PCB-180 was significantly associated with TG ($p = 0.03$) and sum of PCB was moderately associated with TL ($p = 0.09$). Associations between HDL-C and PCB-138 or BDE-99 were positive, while all other moderate and significant associations

between lipid parameters and POPs were negative. Tertile analyses supported analyzing associations as linear relationships (data not shown).

Table 3. Relationship between Chemical Exposures Levels at Delivery and Child Lipid Levels at 6–7 years in the GESTE Cohort.

	Chemical	Bivariate Model			Multivariate Model ⁺		
		Beta	SE	<i>p</i>	Beta	SE	<i>p</i>
Cholesterol ^a	PCB 138	−0.028	(0.014)	0.04	−0.024	(0.014)	0.09
	PCB 153	−0.029	(0.022)	**	−0.022	(0.022)	**
	PCB 180	−0.003	(0.019)	**	0.001	(0.018)	**
	Sum PCB	−0.062	(0.037)	0.09	−0.046	(0.037)	**
	BDE 47	0.020	(0.032)	**	0.029	(0.031)	**
	BDE 100	−0.005	(0.020)	**	−0.004	(0.019)	**
	BDE 99	0.002	(0.018)	**	0.003	(0.018)	**
	BDE 153	−0.009	(0.017)	**	−0.006	(0.017)	**
	Sum BDE	0.011	(0.036)	**	0.015	(0.035)	**
	Sum OH	−0.021	(0.045)	**	−0.007	(0.044)	**
HDL ^b	PCB 138	0.018	(0.010)	0.06	0.018	(0.010)	0.07
	PCB 153	−0.001	(0.016)	**	−0.002	(0.016)	**
	PCB 180	0.015	(0.013)	**	0.015	(0.013)	**
	Sum PCB	0.023	(0.026)	**	0.022	(0.027)	**
	BDE 47	0.026	(0.022)	**	0.025	(0.022)	**
	BDE 100	0.021	(0.013)	**	0.021	(0.014)	**
	BDE 99	0.024	(0.013)	0.06	0.024	(0.013)	0.06
	BDE 153	0.006	(0.012)	**	0.005	(0.012)	**
	Sum BDE	0.041	(0.025)	**	0.041	(0.025)	**
	Sum OH	0.043	(0.031)	**	0.042	(0.031)	**
LDL ^a	PCB 138	−0.026	(0.014)	0.06	−0.022	(0.013)	**
	PCB 153	−0.026	(0.022)	**	−0.022	(0.022)	**
	PCB 180	0.011	(0.018)	**	0.014	(0.018)	**
	Sum PCB	−0.049	(0.036)	**	−0.037	(0.036)	**
	BDE 47	0.012	(0.031)	**	0.022	(0.030)	**
	BDE 100	−0.010	(0.019)	**	−0.007	(0.019)	**
	BDE 99	0.012	(0.018)	**	0.014	(0.018)	**
	BDE 153	−0.017	(0.017)	**	−0.013	(0.016)	**
	Sum BDE	0.005	(0.035)	**	0.011	(0.034)	**
	Sum OH	−0.008	(0.043)	**	0.004	(0.043)	**
Triglycerides ^b	PCB 138	−0.026	(0.011)	0.02	−0.023	(0.011)	0.04
	PCB 153	−0.008	(0.018)	**	0.000	(0.018)	**
	PCB 180	−0.033	(0.015)	0.02	−0.032	(0.015)	0.03
	Sum PCB	−0.046	(0.029)	**	−0.035	(0.030)	**
	BDE 47	−0.015	(0.025)	**	−0.018	(0.025)	**
	BDE 100	−0.014	(0.016)	**	−0.016	(0.015)	**
	BDE 99	−0.041	(0.014)	0.01	−0.043	(0.014)	0.003
	BDE 153	0.016	(0.014)	**	0.015	(0.014)	**
	Sum BDE	−0.024	(0.029)	**	−0.028	(0.028)	**
	Sum OH	−0.060	(0.035)	0.09	−0.055	(0.035)	**
Total lipids ^b	PCB 138	−0.010	(0.004)	0.01	−0.009	(0.004)	0.02
	PCB 153	−0.007	(0.006)	**	−0.004	(0.006)	**
	PCB 180	−0.008	(0.005)	**	−0.007	(0.005)	**
	Sum PCB	−0.022	(0.010)	0.02	−0.017	(0.010)	0.09
	BDE 47	0.001	(0.008)	**	0.002	(0.008)	**
	BDE 100	−0.004	(0.005)	**	−0.004	(0.005)	**
	BDE 99	−0.008	(0.005)	0.09	−0.009	(0.005)	0.07
	BDE 153	0.001	(0.005)	**	0.001	(0.005)	**
	Sum BDE	−0.004	(0.010)	**	−0.004	(0.009)	**
	Sum OH	−0.017	(0.012)	**	−0.013	(0.012)	**

Abbreviations: SE-standard error, P-T-test *p*-value, HDL-high density lipoproteins, LDL-low density lipoproteins, PCB-polychlorinated biphenyl, BDE-brominated diphenyl ether, OH-organohalogen. ^a Beta and SE from model using cholesterol untransformed and log transformed chemicals. ^b Beta and SE from model using log transformed exposure and log transformed outcome. ** *p*-value from T-test ≥ 0.10 . ⁺ Adjusted for mother's age during pregnancy and mother's body mass index after delivery.

We conducted analysis to address potential confounding by childhood chemical levels, which could result in a misattribution of effects of chemical exposure in childhood on lipids as being due to in utero exposure. Because of a primary goal to assess and control for confounding, we first evaluated correlations between in utero chemical levels and those measured in children age 6–7 (Supplemental Table S1) and observed mostly weak relations between maternal chemical levels and those among children at age 6–7. Levels of childhood BDE-153 were correlated with maternal delivery values for BDE-100 ($r = 0.24, p = 0.005$) and BDE-153 ($0.34, p < 0.0001$) ($n = 140$ child-mother pairs). We ran main analyses adjusted for BDE-153 to estimate in utero effects independent of childhood chemical levels (Figure S1) ($n = 136$ child-mother pairs). Generally, results remained the same or were strengthened. We also conducted analysis to evaluate the relationship between age 6–7 years old PBDE exposures with serum lipids (Supplemental Table S2). For these analyses, we utilized wet weight chemicals in order to avoid adjusting exposure for the dependent variable and resulting bias along with interpretational challenges. Associations between childhood levels of BDE-47 and 99 were observed with lower HDL-C and higher LDL-C. BDE-100 was also associated with lower HDL-C.

Analyses stratified by child sex suggested sex-specific associations (Figure 1). In the majority of stratified analyses, the associations among girls and boys were not equivalent to one another nor the non-stratified (“All”) results and followed a similar trend. Nevertheless, tests for interactions between chemical and child sex were not significant in bivariate or adjusted models (Table 4).




Figure 1. Correlations between in utero POP levels and blood lipids in children in the GESTE cohort, overall and separate by child sex: (A)—total cholesterol; (B)—high density lipoproteins; (C)—low density lipoproteins, (D)—triglycerides; (E)—total lipids. Linear regression coefficients are shown from models of lipids measured in children at age 6–7 from the GESTE cohort and in utero levels of PCBs and PBDEs. Squares indicate results in the full cohort ($n = 147$); offspring sex-specific estimates are shown with circles (in male offspring only, $n = 82$) and diamonds (female offspring only, $n = 65$).

Table 4. Interaction between Chemical Exposures Levels at Delivery and Child Biological Sex on Child Lipid Levels at 6–7 years in the GESTE Cohort.

		Bivariate Model	Multivariate Model ⁺
	Chemical	<i>p</i> *	<i>p</i> *
Cholesterol ^a	PCB 138	0.66	0.75
	PCB 153	0.36	0.34
	PCB 180	0.34	0.22
	Sum PCB	0.16	0.14
	BDE 47	0.16	0.18
	BDE 100	0.47	0.55
	BDE 99	0.98	0.75
	BDE 153	0.94	0.99
	Sum BDE	0.48	0.52
	Sum OH	0.27	0.33
HDL ^b	PCB 138	0.56	0.56
	PCB 153	0.45	0.46
	PCB 180	0.29	0.29
	Sum PCB	0.35	0.35
	BDE 47	0.85	0.85
	BDE 100	0.93	0.93
	BDE 99	0.48	0.50
	BDE 153	0.85	0.85
	Sum BDE	0.97	0.96
	Sum OH	0.62	0.63
LDL ^a	PCB 138	0.69	0.77
	PCB 153	0.24	0.21
	PCB 180	0.16	0.08
	Sum PCB	0.15	0.13
	BDE 47	0.17	0.19
	BDE 100	0.34	0.41
	BDE 99	0.70	0.92
	BDE 153	0.91	0.85
	Sum BDE	0.42	0.46
	Sum OH	0.28	0.34
Triglycerides ^b	PCB 138	0.12	0.16
	PCB 153	0.25	0.32
	PCB 180	0.46	0.56
	Sum PCB	0.02	0.02
	BDE 47	0.76	0.76
	BDE 100	0.07	0.08
	BDE 99	0.996	0.88
	BDE 153	0.86	0.80
	Sum BDE	0.50	0.55
	Sum OH	0.38	0.36
Total lipids ^b	PCB 138	0.28	0.37
	PCB 153	0.26	0.28
	PCB 180	0.30	0.25
	Sum PCB	0.03	0.03
	BDE 47	0.47	0.51
	BDE 100	0.59	0.53
	BDE 99	0.95	0.70
	BDE 153	0.97	0.96
	Sum BDE	0.99	0.99
	Sum OH	0.23	0.27

Abbreviations: SE-standard error, P-T-test *p*-value, HDL-high density lipoproteins, LDL-low density lipoproteins, PCB-polychlorinated biphenyl, BDE-brominated diphenyl ether, OH-organohalogenes. ^a Beta and SE from model using cholesterol untransformed and log transformed chemicals. ^b Beta and SE from model using log transformed exposure and log transformed outcome. * *p*-value from Type 3 F-test. ⁺ Adjusted for mother's age during pregnancy and mother's body mass index after delivery. Bold values indicate significant and semi-significant findings.

3. Discussion

Several rodent studies observed long-term programming of lipid metabolism by in utero exposures to POPs [26,27,29–31]. Results from the current study of mother-child pairs in the GESTE cohort suggest that these previously reported findings may apply for humans, as well. In mice, we have found that in utero exposure to PBDEs causes a shift of lipid balance between the liver and blood, whereby increased uptake and accumulation of lipids by the liver results in decreased TG in blood and a NAFLD-like liver phenotype. In our current study, we also observe decreased TG in blood associated with in utero exposures to BDE-99 and PCB-138. Additionally, in utero levels of BDE-99 were associated with lower total lipids, and those of PCB-138 were associated with lower LDL-C and total blood lipids in 6–7-year-old children. These associations between in utero POPs and lower plasma lipid levels are consistent with increased uptake of fatty acids by the liver and may indicate higher fat accumulation in children's livers.

Notably, PCB-138 and BDE-99 had the broadest normalized ranges of exposures among all compounds analyzed, suggesting that weaker associations between other POPs at delivery and lipid profiles at childhood may be due to our limited ability to detect them and/or distribution in the study sample, rather than due to the lack of biological link between exposures and outcomes. In addition, adjustment for POPs measured in childhood plasma samples did not weaken estimates of the in utero exposure effects as represented by maternal plasma levels. The potential for childhood POPs to confound the relationship of in utero exposure with childhood lipid levels depends upon common causes that result in correlation between exposure at these two time points. We did not observe such a correlation in our data, suggesting no substantial confounding of the relationship of interest. This provides further support that association between in utero POPs are due to programming effects rather than due to continuous exposures lasting into childhood, though caution is warranted to acknowledge the potential for chance findings.

Further, we observed indication that programming is sexually dimorphic and that the relationship between in utero POPs and lipid profile in children is sex specific. Because our analysis was inherently restricted to dyads with available data on both in utero chemical levels and childhood lipid levels, our sample size was modest and we had limited statistical power to detect interactions. In analyses stratified on offspring sex, we observed consistent differences in the associations of in utero POPs and childhood lipids. This observation is in agreement with our hypothesis that sex specificity in liver metabolic functions results in modified response of lipid liver metabolism to chemical exposures. Our limited ability to find significant effect of sex may be also explained by the young age of the study participants. Liver sex specificity is generally thought to be established after the onset of puberty, when growth hormone secretion reaches clear sexually dimorphic patterns [32]. Recent research has demonstrated however, that even late gestation fetal livers have well-pronounced sex-specific pattern of gene expression in mice and more than 70% of fetal sex-biased genes overlap with adult sex-biased genes [33]. Comparable data are not available for humans to our knowledge.

To the best of our knowledge, this study is the first epidemiologic investigation of a putative link between in utero exposures to PCBs and PBDEs and long-term changes in serum lipids in humans. Exposure levels to PBDEs in the GESTE cohort are comparable with exposure levels in many studies in the North America as compared elsewhere [34,35]. Maternal plasma levels of PCBs were very close to these in a representative sampling of the U.S. population in the National Health and Examination Survey [36]. Effects of developmental exposures to PBDE on permanent changes in liver lipid metabolism and circulating lipids have been shown in several rodent studies [26,27,29–31]. For example, mice exposed to low doses of BDE-47 perinatally and then kept on a high fat diet for 14 weeks developed dyslipidemia and hepatic steatosis [27]. A significant body of literature exists linking adult exposure to PCBs with altered lipid metabolism, including NAFLD promotion [37]. We were unable to identify studies in which long lasting changes in lipid metabolism outcomes were analyzed following developmental exposures to PCB.

However, in four-month-old rats exposed perinatally to non-dioxin-like PCBs changes in gene expression in blood were significantly enriched for lipid metabolism [38].

Transient activation of liver Phase I-III enzymes via induction of nuclear receptors (xenosensors) by a broad range of xenobiotics is one of the central concepts in toxicology. Given that this same set of nuclear receptors regulates lipid homeostasis [8–18], potential short-term responses to xenobiotics include transient changes in liver lipid metabolism. PBDEs and PCBs are no exception to this rule, as both groups of chemicals are ligands for CAR and PXR xenosensors [25]. In other words, acute effects of PBDE and PCB on lipid levels are predictable and represent a common toxicological response. Positive associations of childhood LDL-C with childhood levels of BDE 47 and 99, as well as negative associations of childhood HDL-C with childhood levels of BDE 47, 99 and 100 correspond to this type of response. These results indicate that ongoing exposures to PBDE may represent a risk factor for cardiovascular disease by shifting the lipid balance toward an increase in “bad cholesterol” and decrease in “good cholesterol” levels.

The major focus of the current study is of a different nature however, as it relates to long-term programming by in utero exposures. Clinically, this is of significance because chronic health conditions arising from in utero programming affect health throughout the lifespan. Molecular mechanisms involved in this programming are not well understood. Our recent studies in rodents suggest that transient activation of the central metabolic master switch, the mTOR pathway [39], in the liver by developmental exposures to PBDE may result in permanent reprogramming of the liver lipid metabolism [26,29] involving changes in the profile of hepatic small non-coding RNA and DNA methylation [28]. It is not clear, however if mTOR activation is mediated via CAR and/or PXR signaling. Understanding of the initial steps triggering liver metabolism reprogramming is complicated by the presence of several transcript variants of CAR [40] and PXR [41], which may have different affinity for different PCB and PBDE congeners; their different downstream mode of action [42]; and emerging evidence of mechanistic links between these receptors and the mTOR pathway [42,43]. Additionally, effects of lipid metabolism reprogramming by POPs may have different effects in males and females due to the sex-specific differences in liver expression of many lipid metabolism genes [22].

Higher lipid uptake by the liver due to long term effects of in utero exposure to POPs, as we report for some chemicals in this pilot study, may contribute to pediatric NAFLD, the most common chronic liver disease in American children [44–46] with an estimated prevalence of 13% [45]. Emerging data demonstrates that pediatric NAFLD may be a more aggressive form of liver disease than adult NAFLD [47]. For example, in a recent study of children with NAFLD, one third of participants developed *nonalcoholic steatohepatitis* (NASH) or worsening of fibrosis in a 2-year period [48]. Severely obese adolescents have significantly higher NASH incidence and liver fibrosis than adults [49]. Pediatric NAFLD is associated with greater liver-related morbidity and mortality in adulthood [50]. Identifying potentially modifiable factors that contribute to these outcomes, and development of future interventions, is thus of great public health significance.

Some limitations and cautions are important to note. In our analysis, we expressed PCB and PBDE concentrations per blood volume without adjustment for blood lipids. For our study of in utero POPs, fetal exposure results from total POPs delivered to placenta via maternal circulation regardless of maternal body burden. The lipophilic nature of PCBs and PBDEs presents a challenge for environmental epidemiologic research, and thoughtful consideration of the underlying biology is a critical step to guide statistical analysis [51]. Lipid normalization is not appropriate when circulating chemical levels, rather than total body burden, is the biologically relevant tissue [51]. Additionally, lipid profile itself may be affected by exposures to POPs [26,29,52–54]. For statistical modeling of outcomes affected by lipids, or lipids themselves, adjustment or use of lipid standardization results in bias to the parameter of interest [51]. Finally, in blood, many POPs are bound to blood proteins. For example, PBDEs and their metabolites have high affinity to transthyretin

in humans [55–57] and to major urinary protein in mice [58]. In that case, adjustment for lipids is not relevant for any biologically meaningful estimation of exposure.

Uncontrolled confounding is always a potential source of bias for observational research. Nevertheless, we were able to adjust for factors including child chemical levels and other variables from the rich GESTE dataset that might represent confounders. Reassuringly, adjustment for covariates had minimal effect on estimates. Thus, through some variables play roles in the relationship of in utero exposure and child lipid levels that are uncertain, such as adiposity which may be a confounder or causal intermediate, results were not impacted. *A priori* power calculations for this exploratory study suggested adequate sample size for the study but did not explicitly address the multiple comparisons due to the number of chemical exposures and lipid outcomes. Results of this exploratory study should be interpreted with caution, accordingly.

One limitation of this study is that lipids were analyzed in non-fasting blood samples collected from children. As a result, child lipid levels are subject to post-prandial variation. Recent studies suggest however, that non-fasting total cholesterol, HDL-C and LDL-C change minimally in response to food intake and may be superior to fasting levels in predicting adverse health outcomes [59–63]. Specifically, a cross-sectional study of more than 200,000 lipid profiles [64] observed that fasting times account for less than 2% variation for total cholesterol and HDL-C and less than 20% for TG. Given that humans are rarely present in fasting state, non-fasting lipids may better present individual molecular reactions of the organism for lipid intake. As such, non-fasting lipid profiles are becoming more popular as markers of health conditions in clinical guidelines [65–68]. Thus, using non-fasting lipids in our study is a moderate limitation as it represents one clinically relevant way to assess lipid profiles. No systematic error is anticipated from this procedure as soon as all within study comparisons are based on non-fasting lipids.

4. Materials and Methods

4.1. Participants

We conducted analyses using data from the prospective GESTE cohort, which is described in detail elsewhere [34,35,69,70]. In short, GESTE cohort is comprised of (a) women residing in the Eastern Townships (Estrie) of Quebec, Canada having a pregnancy between 2007 and 2009 and (b) children born from these pregnancies. Women were recruited at their first prenatal visit by 20 weeks gestational age ($n = 400$, at >20 weeks), or at delivery ($n = 400$ additional women) at the Research Center of the Centre Hospitalier Universitaire de Sherbrooke (CHUS). Eligible criteria included women ≥ 18 years old at their first prenatal visit without thyroid diseases, who were planning on residing in the Estrie for at least three years. At delivery, only healthy, uncomplicated term pregnancies were included in the cohort.

Our study population was restricted to maternal-child dyads including women with singleton pregnancies, having complete data for maternal PBDEs at delivery as well as a lipid profile performed at age 6–7 years old. After applying these inclusion criteria, a total of 147 observations were included for analysis.

The Institutional Review Boards of the CHUS, Université de Sherbrooke (IRB # 05-057-S1, 2008-103), Health Canada (REB 2017-035H) and the University of Massachusetts, Amherst (IRB # 2019-5622), approved study protocols, and women provided informed consent for themselves and their children.

4.2. Data Collection

Data were collected and managed using the secure online platform REDCap [71]. Non-fasting maternal blood was collected at delivery in 10-mL Vacutainer® Hemogard tubes with ethylenediaminetetraacetic acid (ref. 366643, Becton-Dickinson, San Jose, CA, USA). The plasma was frozen at -20 °C in decontaminated Supelco glass storage tubes (Supelco, Inc., Bellefonte, PA, USA) for PBDEs and PCBs. In addition, 10-mL metal-free blood collection tubes with 0.05 mL of 15% ethylenediaminetetraacetic acid K3 stored at 4

°C were used for manganese, lead, mercury and cadmium analysis. At the age of 6–7 years old, ten mL of non-fasting whole blood were taken from each child using a BD Vacutainer® tubes (ref. 367962, Becton Dickinson, Franklin Lakes, NY, USA) containing lithium-heparin for the analysis of PBDEs and lipid profiles. Non fasting blood samples were stored at –80 °C and analyzed for lipid profiles in the core laboratory of the CHUS.

4.3. Exposure Assessment—PBDEs and PCBs in Utero and at 6–7

Maternal plasma levels of PBDEs (BDE-47, BDE-99, BDE-100, and BDE-153) and PCBs (PCB-138, PCB-153, and PCB-180) were analyzed in the laboratory of L. Takser (Université de Sherbrooke) using the method described by Covaci and Voorspoels [72]. As previously described, [34,35], analytes were quantified using Varian 4000 Ion Trap GC/MS-MS (gas chromatograph/tandem mass spectrometer) (Varian Inc., CA, USA). Quality control was conducted through regular analyses of water blanks, solvent blanks and random duplicate samples. All blanks were subtracted from sample values on a batch basis. Inter-batch coefficients of variation were $\leq 10\%$ and $\leq 8\%$ for PBDEs and PCBs, respectively. Limits of detection (LOD), defined as 3 times the noise level, were established at 0.1 pg/ μL for PBDEs and at 0.02 pg/ μL for PCBs. Routine checks of accuracy and precision were also performed using reference materials (1589a) from the National Institute of Standards and Technology (Gaithersburg, MD, USA). Recoveries ranged between 75 and 125%.

Child plasma PBDE levels were analyzed in the laboratory of J. Zhu (Health Canada). Analytical procedures are described in detail elsewhere [69]. In short, analytes were quantified using an Agilent 7890A GC coupled with 7200 QTOF MS (Agilent Technologies, Santa Clara, CA, USA). Quality control was conducted through regular analyses of water blanks, commercial human serum (S7023, Sigma Aldrich, MO, USA) that was spiked with target analytes, and random duplicate samples. All blanks were subtracted from sample values on a batch basis. Inter-batch coefficients of variation were in a range between 1% and 9% for different PBDE congeners. Compound specific limit of detection (LOD) was estimated to be in the range of 1–5 pg/g wet weight. Mean recoveries were in the range of 94–125%, except for BDE-183 (59.6%). The concentrations of target analytes in the samples were recovery-corrected against BDE-138, a congener that was not present in the environment and humans, as the surrogate standard.

4.4. Outcome Assessment—Lipid Profiles in Children at Age 6–7

The lipid work-up was performed in the the biochemistry laboratory of the CHUS. Fresh blood samples were centrifuged at 1300–2000 g for 10 min to separate the plasma from the whole blood within 1 h after collection. Samples were stored at –80 °C. Total cholesterol (TCh) (assay ref. 5168538), total triglycerides (TG) (assay ref. 5171407), and high density lipoproteins (HDL-C) (assay ref. 5168805) were analyzed using enzymatic colorimetric method using a Roche Cobas 8000 analyzer with commercial c702 kit, following manufacturer's instructions (Roche Diagnostics, Germany). The assay was calibrated for each new reagent bottle or batch or when required by internal control. Analytical variation and systematic error were both below 3% [69]. Lower limits of detection (LOD) were 0.1 mmol/L (3.86 mg/dL) for TCh, 0.08 mmol/L (3 mg/dL) for HDL-C and 0.1 mmol/L (8.85 mg/dL) for TG. Concentration of low-density lipoproteins (LDL-C) was estimated using the Friedewald formula ($\text{LDL} = \text{TCh} - \text{HDL} - \text{TG}/2.2$) [73] and concentration of total lipids (TL) was estimated using Phillips formula ($\text{TL} = 2.27\text{TCh} + \text{TG} + 0.62$) [74,75].

4.5. Additional Covariates in GESTE

Additional data collected in the GESTE study were utilized to characterize the study sample and to address potential confounding by factors with effects on child lipid levels and correlated with in utero POPs. Questionnaires were administered by interviewers at the first prenatal visit and after delivery and were used to collect information on education, income, alcohol consumption, smoking and other factors [35]. Trained staff measured women's height and weight at the enrolment visit and collected self-reported information

on the usual weight and height after delivery. Children's height and weight was similarly assessed at the age 6–7 years old. All data on maternal health and obstetrical history, medication use, and delivery were obtained from medical records.

In addition to questionnaire data, data for metals was considered as metal exposures have been shown in many studies to affect lipid metabolism (reviewed in [76]). Whole blood manganese, lead, cadmium and mercury were determined by the Toxicology Center of Quebec at the Quebec Institute for Public Health (CTQ-INSPQ) as described elsewhere [34,35]. In short, cold vapor atomic absorption spectrophotometry was used for total blood mercury and mass spectrometry plasma torch (ICP-MS) for lead, cadmium and manganese. Limits of detection were 2.07 µg/L for lead, 0.1 µg/L for mercury, 0.05 µg/L for cadmium, and 4.4 µg/L for manganese.

4.6. Data Management and Statistical Analyses

Chemical levels below the LOD were set to LOD/2. In order to address outliers related to measurement error and undue leverage in analysis, values higher than 3.5 standard deviations above the mean were replaced by this cut point [77]. Some variables were natural log transformed based on the visual inspections of distributions to meet distributional assumptions for statistical modeling.

Generalized linear models (GLM) were used to evaluate the relation of childhood lipid levels as continuous variables with in utero POPs. The interpretation of regression coefficients varies depending on whether a log transformation was used for independent and dependent variables. In recognition of the limited statistical power for this pilot study, a conservative approach to specifying multivariable models was used to build parsimonious models, aimed at maximizing statistical power while controlling for confounding. Using underlying biology and existing literature, a priori potential confounding factors based on plausible causal relations with child lipid levels and POP exposures was identified. These a priori potential confounders included: maternal age (years); smoking during pregnancy; alcohol using during pregnancy; child sex (male/female); maternal education; maternal body mass index at 1st trimester and after delivery (BMI, (weight (kg) / [height (m)]²)); child's weight and BMI at age 6–7; delivery type (vaginal, caesarean, missing); gestational diabetes during current pregnancy; maternal delivery and 6–7 year children's serum levels of lead, cadmium, manganese, and mercury. Only those factors related to both outcome and exposure ($p < 0.20$) were retained in final models to address confounding, as determined from ANOVA for categorical variables and generalized linear models for continuous variables. For the primary statistical models of lipids, chemical exposures were included as continuous variables. To evaluate departures from the assumption of linearity in the GLM models, chemical exposures were categorized into tertiles. Regression models of serum lipid outcomes were run as non-parametric assessments of dose–response patterns.

We utilized data on age 6–7 child chemical levels to account for potential confounding of in utero chemical effects by later life exposure. Using available data on chemical levels measured at age 6–7 (including BDE-100, BDE-99, BDE-153, and BDE-183), we evaluated associations with maternal delivery levels by correlation analysis, and associations with child lipid levels using GLMs. Finally, multivariable regression models were run including childhood POPs related to in utero exposures and child lipid outcomes as covariates in order to estimate effects of in utero exposure independent of later life chemical levels.

In addition to the main analyses described above, we evaluated differences by offspring sex to address sex-differences in associations by performing stratified analyses as well as including a cross-product interaction term. This interaction term was used to test additive interaction between child sex and exposure. For all analyses, statistical significance was defined as p -values < 0.05 .

5. Conclusions

In the current study, our data are consistent with long-term effects of in utero environmental exposures to PCB and PBDE on blood lipids, previously observed in murine

models, but to this date, not assessed in humans. Relationships between higher in utero POPs and lower childhood blood lipids may indicate increased lipid accumulation in livers, a mechanism of NAFLD development. Additionally, we observed shift in children lipid profiles by ongoing exposures to several PBDE congeners, consisting in the increased LDL-C and decreased HDL-C, a potential risk factor for cardiovascular disease. Our study provides suggestion that long-term changes in blood lipids may be sexually dimorphic, in line with well-established sexual dimorphism in liver physiology. Given the modest sample size of our study and recognition that this sexual dimorphism and implications for lipid metabolism increase drastically after puberty, further research on bigger child cohorts as well as on adult subjects is needed to study long-term programming of liver lipid metabolism and sex-specific effects of developmental exposures to POPs.

Supplementary Materials: The following are available online at <https://www.mdpi.com/article/10.3390/metabo11100657/s1>, Figure S1: Correlations between POP and lipid levels in blood of 6–7 years old children in the GESTE cohort, overall and separate by child sex: A—total cholesterol; B—high density lipoproteins; C—low density lipoproteins, D—triglycerides; E—total lipids. Squares indicate results in the full cohort (n = 147); offspring sex-specific estimates are shown with circles (in male offspring only, n = 82) and diamonds (female offspring only, n = 65), Table S1: Pearson correlation coefficients and p-values for serum delivery and serum child organohalogen levels, GESTE Cohort. Table S2: Relationship between Chemical Exposures Levels at 6–7 years and Child Lipid Levels at 6–7 years in the GESTE Cohort.

Author Contributions: Conceptualization, B.W.W. and A.S.; methodology, M.E.B, J.Z. and A.S.; formal analysis, M.E.B., B.W.W, A.B., A.C., V.G., G.M., J.-C.P., J.Z., L.T., L.S.-C. and A.S.; investigation, M.E.B., B.W.W., A.B., A.C., V.G., G.M., J.Z. and A.S.; validation and visualization, M.E.B., B.W.W., J.Z. and A.S.; roles/writing—original draft, M.E.B., B.W.W. and A.S.; writing—review and editing, M.E.B., B.W.W, A.B., A.C., V.G., J.-C.P., J.Z., L.T., L.S.-C. and A.S.; funding acquisition, B.W.W., L.T. and A.S.; project administration, B.W.W., A.B., V.G., L.T. and A.S.; resources, B.W.W, A.B., V.G., J.-C.P., J.Z., L.T., L.S.-C. and A.S.; supervision, B.W.W., L.T. and A.S.; data curation, N.A., A.A.B., A.B., V.G., L.T. and L.S.-C. All authors have read and agreed to the published version of the manuscript.

Funding: This study was supported by the US National Institute of Health (R21 ES029686-01A1). The GESTE cohort was financed by grant 12397 from the Fonds de Recherche du Québec-Santé (FRQS), grant MOP-84551 from the Canadian Institutes of Health Research (CIHR), grants from the National Institute of Environmental Health Sciences (R21ES024841, P30ES009089, K23ES022242) and by the Canadian Government Chemicals Management Plan. Study protocols were approved by the Institutional Review Boards of the CHUS, Université de Sherbrooke (IRB # 05-057-S1, 2008-103), Health Canada (REB 2017-035H) and the University of Massachusetts, Amherst (IRB # 2019-5622).

Institutional Review Board Statement: The Institutional Review Boards of the CHUS, Université de Sherbrooke (IRB # 05-057-S1, 2008-103), Health Canada (REB 2017-035H) and the University of Massachusetts, Amherst (IRB # 2019-5622), approved study protocols.

Informed Consent Statement: Informed consent was obtained from all subjects involved in the study. Women, subjects of this study, provided informed consent for themselves and their children.

Data Availability Statement: Data are available on request to the PI of the GESTE cohort L.Takser due to protect human subjects.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Hites, R.A. Polybrominated diphenyl ethers in the environment and in people: A meta-analysis of concentrations. *Environ. Sci. Technol.* **2004**, *38*, 945–956. [[CrossRef](#)]
2. Hurley, S.; Goldberg, D.; Nelson, D.O.; Guo, W.; Wang, Y.; Baek, H.G.; Park, J.S.; Petreas, M.; Bernstein, L.; Anton-Culver, H.; et al. Temporal Evaluation of Polybrominated Diphenyl Ether (PBDE) Serum Levels in Middle-Aged and Older California Women, 2011–2015. *Environ. Sci. Technol.* **2017**, *51*, 4697–4704. [[CrossRef](#)]
3. Geyer, H.J.; Schramm, K.W.; Feicht, E.A.; Fried, K.W.; Henkelmann, B.; Lenoir, D.; Darnerud, P.O.; Aune, M.; Schmid, P.; McDonald, T.A. Terminal Elimination Half-lives of the Brominated Flame Retardants TBBPA, HBCD, and Lower Brominated PBDEs in Humans. *Organohalogen Compd.* **2004**, *66*, 3820–3825.

4. Szabo, D.T.; Diliberto, J.J.; Hakk, H.; Huwe, J.K.; Birnbaum, L.S. Toxicokinetics of the flame retardant hexabromocyclododecane alpha: Effect of dose, timing, route, repeated exposure, and metabolism. *Toxicol. Sci.* **2011**, *121*, 234–244. [[CrossRef](#)] [[PubMed](#)]
5. Antignac, J.P.; Cariou, R.; Maume, D.; Marchand, P.; Monteau, F.; Zalko, D.; Berrebi, A.; Cravedi, J.-P.; Andre, F.; Le Bizec, B. Exposure assessment of fetus and newborn to brominated flame retardants in France: Preliminary data. *Mol. Nutr. Food Res.* **2008**, *52*, 258–265. [[CrossRef](#)]
6. Herbstman, J.B.; Sjodin, A.; Apelberg, B.J.; Witter, F.R.; Patterson, D.G.; Halden, R.U.; Jones, R.S.; Park, A.; Zhang, Y.; Heidler, J.; et al. Determinants of prenatal exposure to polychlorinated biphenyls (PCBs) and polybrominated diphenyl ethers (PBDEs) in an urban population. *Environ. Health Perspect.* **2007**, *115*, 1794–1800. [[CrossRef](#)]
7. Doucet, J.; Tague, B.; Arnold, D.L.; Cooke, G.M.; Hayward, S.; Goodyer, C.G. Persistent organic pollutant residues in human fetal liver and placenta from Greater Montreal, Quebec: A longitudinal study from 1998 through 2006. *Environ. Health Perspect.* **2009**, *117*, 605–610. [[CrossRef](#)]
8. Berger, J.; Moller, D.E. The mechanisms of action of PPARs. *Annu. Rev. Med.* **2002**, *53*, 409–435. [[CrossRef](#)] [[PubMed](#)]
9. Wang, Y.X. PPARs: Diverse regulators in energy metabolism and metabolic diseases. *Cell Res.* **2010**, *20*, 124–137. [[CrossRef](#)]
10. Liss, K.H.; Finck, B.N. PPARs and nonalcoholic fatty liver disease. *Biochimie* **2017**, *136*, 65–74. [[CrossRef](#)]
11. Gross, B.; Pawlak, M.; Lefebvre, P.; Staels, B. PPARs in obesity-induced T2DM, dyslipidaemia and NAFLD. *Nat. Rev. Endocrinol.* **2017**, *13*, 36–49. [[CrossRef](#)]
12. Pawlak, M.; Lefebvre, P.; Staels, B. Molecular mechanism of PPARalpha action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease. *J. Hepatol.* **2015**, *62*, 720–733. [[CrossRef](#)] [[PubMed](#)]
13. Kublbeck, J.; Niskanen, J.; Honkakoski, P. Metabolism-Disrupting Chemicals and the Constitutive Androstane Receptor CAR. *Cells* **2020**, *9*, 2306. [[CrossRef](#)]
14. Helsley, R.N.; Sui, Y.; Ai, N.; Park, S.H.; Welsh, W.J.; Zhou, C. Pregnane X receptor mediates dyslipidemia induced by the HIV protease inhibitor amprenavir in mice. *Mol. Pharmacol.* **2013**, *83*, 1190–1199. [[CrossRef](#)] [[PubMed](#)]
15. Cheng, J.; Krausz, K.W.; Tanaka, N.; Gonzalez, F.J. Chronic exposure to rifaximin causes hepatic steatosis in pregnane X receptor-humanized mice. *Toxicol. Sci.* **2012**, *129*, 456–468. [[CrossRef](#)] [[PubMed](#)]
16. Spruiell, K.; Richardson, R.M.; Cullen, J.M.; Awumey, E.M.; Gonzalez, F.J.; Gyamfi, M.A. Role of pregnane X receptor in obesity and glucose homeostasis in male mice. *J. Biol. Chem.* **2014**, *289*, 3244–3261. [[CrossRef](#)] [[PubMed](#)]
17. Wada, T.; Sunaga, H.; Miyata, K.; Shirasaki, H.; Uchiyama, Y.; Shimba, S. Aryl Hydrocarbon Receptor Plays Protective Roles against High Fat Diet (HFD)-induced Hepatic Steatosis and the Subsequent Lipotoxicity via Direct Transcriptional Regulation of Socs3 Gene Expression. *J. Biol. Chem.* **2016**, *291*, 7004–7016. [[CrossRef](#)] [[PubMed](#)]
18. Wang, B.L.; Zhang, C.W.; Wang, L.; Tang, K.L.; Tanaka, N.; Gonzalez, F.J.; Xu, Y.; Fang, Z.-Z. Lipidomics reveal aryl hydrocarbon receptor (Ahr)-regulated lipid metabolic pathway in alpha-naphthyl isothiocyanate (ANIT)-induced intrahepatic cholestasis. *Xenobiotica* **2019**, *49*, 591–601. [[CrossRef](#)] [[PubMed](#)]
19. Clodfelter, K.H.; Holloway, M.G.; Hodor, P.; Park, S.H.; Ray, W.J.; Waxman, D.J. Sex-dependent liver gene expression is extensive and largely dependent upon signal transducer and activator of transcription 5b (STAT5b): STAT5b-dependent activation of male genes and repression of female genes revealed by microarray analysis. *Mol. Endocrinol.* **2006**, *20*, 1333–1351. [[CrossRef](#)]
20. Rinn, J.L.; Rozowsky, J.S.; Laurenzi, I.J.; Petersen, P.H.; Zou, K.; Zhong, W.; Gerstein, W.; Snyder, M. Major molecular differences between mammalian sexes are involved in drug metabolism and renal function. *Dev. Cell* **2004**, *6*, 791–800. [[CrossRef](#)]
21. Kwekel, J.C.; Desai, V.G.; Moland, C.L.; Branham, W.S.; Fuscoe, J.C. Age and sex dependent changes in liver gene expression during the life cycle of the rat. *BMC Genom.* **2010**, *11*, 675. [[CrossRef](#)]
22. Zhang, Y.; Klein, K.; Sugathan, A.; Nassery, N.; Dombkowski, A.; Zanger, U.M.; Waxman, D.J. Transcriptional profiling of human liver identifies sex-biased genes associated with polygenic dyslipidemia and coronary artery disease. *PLoS ONE* **2011**, *6*, e23506. [[CrossRef](#)] [[PubMed](#)]
23. Lau-Corona, D.; Suvorov, A.; Waxman, D.J. Feminization of male mouse liver by persistent growth hormone stimulation: Activation of sex-biased transcriptional networks and dynamic changes in chromatin states. *Mol. Cell. Biol.* **2017**, *37*, e00301-17. [[CrossRef](#)]
24. Waxman, D.J.; Holloway, M.G. Sex differences in the expression of hepatic drug metabolizing enzymes. *Mol. Pharmacol.* **2009**, *76*, 215–228. [[CrossRef](#)] [[PubMed](#)]
25. Dingemans, M.M.; Kock, M.; van den Berg, M. Mechanisms of Action Point Towards Combined PBDE/NDL-PCB Risk Assessment. *Toxicol. Sci.* **2016**, *153*, 215–224. [[CrossRef](#)] [[PubMed](#)]
26. Khalil, A.; Parker, M.; Mpanga, R.; Cevik, E.C.; Thorburn, C.; Suvorov, A. Developmental Exposure to 2,2',4,4'-Tetrabromodiphenyl Ether Induces Long-Lasting Changes in Liver Metabolism in Male Mice. *J. Endocr. Soc.* **2017**, *1*, 323–344. [[CrossRef](#)] [[PubMed](#)]
27. Wang, D.; Yan, J.; Teng, M.; Yan, S.; Zhou, Z.; Zhu, W. In utero and lactational exposure to BDE-47 promotes obesity development in mouse offspring fed a high-fat diet: Impaired lipid metabolism and intestinal dysbiosis. *Arch. Toxicol.* **2018**, *92*, 1847–1860. [[CrossRef](#)]
28. Suvorov, A.; Naumov, V.; Shtratnikova, V.; Logacheva, M.; Shershebnov, A.; Wu, H.; Gerasimov, E.; Zheludkevich, A.; Pilsner, J.R.; Sergeyev, O. Rat liver epigenome programming by perinatal exposure to 2,2',4,4'-tetrabromodiphenyl ether. *Epigenomics* **2020**, *12*, 235–249. [[CrossRef](#)] [[PubMed](#)]
29. Khalil, A.; Cevik, S.E.; Hung, S.; Kolla, S.; Roy, M.A.; Suvorov, A. Developmental Exposure to 2,2',4,4'-Tetrabromodiphenyl Ether Permanently Alters Blood-Liver Balance of Lipids in Male Mice. *Front. Endocrinol. (Lausanne)* **2018**, *9*, 548. [[CrossRef](#)]

30. Suvorov, A.; Takser, L. Global Gene Expression Analysis in the Livers of Rat Offspring Perinatally Exposed to Low Doses of 2,2',4,4'-tetrabromodiphenyl ether. *Environ. Health Perspect.* **2010**, *118*, 97–102. [[CrossRef](#)]
31. Gomez, M.V.; Dutta, M.; Suvorov, A.; Shi, X.; Gu, H.; Mani, S.; Cui, J.Y. Early life exposure to environmental contaminants (BDE-47, TBBPA, and BPS) produced persistent alterations in fecal microbiome in adult male mice. *Toxicol. Sci.* **2020**, *179*, 14–30. [[CrossRef](#)] [[PubMed](#)]
32. Chowen, J.A.; Frago, L.M.; Argente, J. The regulation of GH secretion by sex steroids. *Eur. J. Endocrinol.* **2004**, *151* (Suppl. 3), U95–U100. [[CrossRef](#)] [[PubMed](#)]
33. Lowe, R.; Gemma, C.; Rakyán, V.K.; Holland, M.L. Sexually dimorphic gene expression emerges with embryonic genome activation and is dynamic throughout development. *BMC Genom.* **2015**, *16*, 295. [[CrossRef](#)] [[PubMed](#)]
34. Serme-Gbedo, Y.K.; Abdelouahab, N.; Pasquier, J.C.; Cohen, A.A.; Takser, L. Maternal levels of endocrine disruptors, polybrominated diphenyl ethers, in early pregnancy are not associated with lower birth weight in the Canadian birth cohort GESTE. *Environ. Health* **2016**, *15*, 49. [[CrossRef](#)]
35. Abdelouahab, N.; Langlois, M.F.; Lavoie, L.; Corbin, F.; Pasquier, J.C.; Takser, L. Maternal and cord-blood thyroid hormone levels and exposure to polybrominated diphenyl ethers and polychlorinated biphenyls during early pregnancy. *Am. J. Epidemiol.* **2013**, *178*, 701–713. [[CrossRef](#)] [[PubMed](#)]
36. Needham, L.L.; Barr, D.B.; Caudill, S.P.; Pirkle, J.L.; Turner, W.E.; Osterloh, J.; Jones, R.L.; Sampson, E.J. Concentrations of environmental chemicals associated with neurodevelopmental effects in U.S. population. *Neurotoxicology* **2005**, *26*, 531–545. [[CrossRef](#)]
37. Shan, Q.; Li, H.; Chen, N.; Qu, F.; Guo, J. Understanding the Multiple Effects of PCBs on Lipid Metabolism. *Diabetes Metab. Syndr. Obes.* **2020**, *13*, 3691–3702. [[CrossRef](#)]
38. De Boever, P.; Wens, B.; Boix, J.; Felipo, V.; Schoeters, G. Perinatal exposure to purity-controlled polychlorinated biphenyl 52, 138, or 180 alters toxicogenomic profiles in peripheral blood of rats after 4 months. *Chem. Res. Toxicol.* **2013**, *26*, 1159–1167. [[CrossRef](#)]
39. Laplante, M.; Sabatini, D.M. mTOR signaling in growth control and disease. *Cell* **2012**, *149*, 274–293. [[CrossRef](#)]
40. Wahlang, B.; Falkner, K.C.; Clair, H.B.; Al-Eryani, L.; Prough, R.A.; States, J.C.; Coslo, D.M.; Omiecinski, C.J.; Cave, M.C. Human receptor activation by aroclor 1260, a polychlorinated biphenyl mixture. *Toxicol. Sci.* **2014**, *140*, 283–297. [[CrossRef](#)]
41. Lin, Y.S.; Yasuda, K.; Assem, M.; Cline, C.; Barber, J.; Li, C.W.; Kholodovych, V.; Ai, N.; Chen, J.D.; Welsh, W.J.; et al. The major human pregnane X receptor (PXR) splice variant, PXR.2, exhibits significantly diminished ligand-activated transcriptional regulation. *Drug Metab. Dispos.* **2009**, *37*, 1295–1304. [[CrossRef](#)]
42. Hardesty, J.E.; Wahlang, B.; Falkner, K.C.; Clair, H.B.; Clark, B.J.; Ceresa, B.P.; Prough, R.A.; Cave, M.C. Polychlorinated biphenyls disrupt hepatic epidermal growth factor receptor signaling. *Xenobiotica* **2017**, *47*, 807–820. [[CrossRef](#)] [[PubMed](#)]
43. Esposito, G.; Gigli, S.; Seguella, L.; Nobile, N.; D'Alessandro, A.; Pesce, M.; Capoccia, E.; Steardo, L.; Cirillo, C.; Cirillo, C.; et al. Rifaximin, a non-absorbable antibiotic, inhibits the release of pro-angiogenic mediators in colon cancer cells through a pregnane X receptor-dependent pathway. *Int. J. Oncol.* **2016**, *49*, 639–645. [[CrossRef](#)]
44. Patton, H.M.; Sirlin, C.; Behling, C.; Middleton, M.; Schwimmer, J.B.; Lavine, J.E. Pediatric nonalcoholic fatty liver disease: A critical appraisal of current data and implications for future research. *J. Pediatr. Gastroenterol. Nutr.* **2006**, *43*, 413–427. [[CrossRef](#)]
45. Schwimmer, J.B.; Deutsch, R.; Kahen, T.; Lavine, J.E.; Stanley, C.; Behling, C. Prevalence of fatty liver in children and adolescents. *Pediatrics* **2006**, *118*, 1388–1393. [[CrossRef](#)] [[PubMed](#)]
46. Younossi, Z.M.; Blissett, D.; Blissett, R.; Henry, L.; Stepanova, M.; Younossi, Y.; Racila, A.; Hunt, S.; Beckerman, R. The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe. *Hepatology* **2016**, *64*, 1577–1586. [[CrossRef](#)]
47. Kohli, R.; Boyd, T.; Lake, K.; Dietrich, K.; Nicholas, L.; Balistreri, W.F.; Ebach, D.; Shashidhar, H.; Xanthakos, S.A. Rapid progression of NASH in childhood. *J. Pediatr. Gastroenterol. Nutr.* **2010**, *50*, 453–456. [[CrossRef](#)] [[PubMed](#)]
48. Xanthakos, S.A.; Lavine, J.E.; Yates, K.P.; Schwimmer, J.B.; Molleston, J.P.; Rosenthal, P.; Murray, K.F.; Vos, M.B.; Jain, A.K.; Scheimann, A.O.; et al. Progression of Fatty Liver Disease in Children Receiving Standard of Care Lifestyle Advice. *Gastroenterology* **2020**, *159*, 1731–1751.e10. [[CrossRef](#)]
49. Holterman, A.X.; Guzman, G.; Fantuzzi, G.; Wang, H.; Aigner, K.; Browne, A.; Holterman, M. Nonalcoholic fatty liver disease in severely obese adolescent and adult patients. *Obesity* **2013**, *21*, 591–597. [[CrossRef](#)]
50. Feldstein, A.E.; Charatcharoenwitthaya, P.; Treeprasertsuk, S.; Benson, J.T.; Enders, F.B.; Angulo, P. The natural history of non-alcoholic fatty liver disease in children: A follow-up study for up to 20 years. *Gut* **2009**, *58*, 1538–1544. [[CrossRef](#)]
51. Schisterman, E.F.; Whitcomb, B.W.; Louis, G.M.; Louis, T.A. Lipid adjustment in the analysis of environmental contaminants and human health risks. *Environ. Health Perspect.* **2005**, *113*, 853–857. [[CrossRef](#)]
52. Goncharov, A.; Haase, R.F.; Santiago-Rivera, A.; Morse, G.; Akwesasne Task Force on the Environment; McCaffrey, R.J.; Rej, R.; Carpenter, D.A. High serum PCBs are associated with elevation of serum lipids and cardiovascular disease in a Native American population. *Environ. Res.* **2008**, *106*, 226–239. [[CrossRef](#)]
53. Lee, D.H.; Steffes, M.W.; Sjodin, A.; Jones, R.S.; Needham, L.L.; Jacobs, D.R., Jr. Low dose organochlorine pesticides and polychlorinated biphenyls predict obesity, dyslipidemia, and insulin resistance among people free of diabetes. *PLoS ONE* **2011**, *6*, e15977. [[CrossRef](#)]
54. Hennig, B.; Reiterer, G.; Toborek, M.; Matveev, S.V.; Daugherty, A.; Smart, E.; Robertson, L.W. Dietary fat interacts with PCBs to induce changes in lipid metabolism in mice deficient in low-density lipoprotein receptor. *Environ. Health Perspect.* **2005**, *113*, 83–87. [[CrossRef](#)]

55. Qin, W.P.; Li, C.H.; Guo, L.H.; Ren, X.M.; Zhang, J.Q. Binding and activity of polybrominated diphenyl ether sulfates to thyroid hormone transport proteins and nuclear receptors. *Environ. Sci. Process. Impacts* **2019**, *21*, 950–956. [[CrossRef](#)]
56. Meerts, I.A.; van Zanden, J.J.; Luijckx, E.A.; van Leeuwen-Bol, I.; Marsh, G.; Jakobsson, E.; Bergman, Å.; Brouwer, A. Potent competitive interactions of some brominated flame retardants and related compounds with human transthyretin in vitro. *Toxicol. Sci.* **2000**, *56*, 95–104. [[CrossRef](#)]
57. Hamers, T.; Kamstra, J.H.; Sonneveld, E.; Murk, A.J.; Kester, M.H.; Andersson, P.L.; Legler, J.; Brouwer, A. In vitro profiling of the endocrine-disrupting potency of brominated flame retardants. *Toxicol. Sci.* **2006**, *92*, 157–173. [[CrossRef](#)]
58. Staskal, D.F.; Hakk, H.; Bauer, D.; Diliberto, J.J.; Birnbaum, L.S. Toxicokinetics of polybrominated diphenyl ether congeners 47, 99, 100, and 153 in mice. *Toxicol. Sci.* **2006**, *94*, 28–37. [[CrossRef](#)] [[PubMed](#)]
59. Langsted, A.; Freiberg, J.J.; Nordestgaard, B.G. Fasting and nonfasting lipid levels: Influence of normal food intake on lipids, lipoproteins, apolipoproteins, and cardiovascular risk prediction. *Circulation* **2008**, *118*, 2047–2056. [[CrossRef](#)] [[PubMed](#)]
60. Mora, S.; Rifai, N.; Buring, J.E.; Ridker, P.M. Fasting compared with nonfasting lipids and apolipoproteins for predicting incident cardiovascular events. *Circulation* **2008**, *118*, 993–1001. [[CrossRef](#)] [[PubMed](#)]
61. Watts, G.F.; Cohn, J.S. Whither the lipid profile: Feast, famine, or no free lunch? *Clin. Chem.* **2011**, *57*, 363–365. [[CrossRef](#)] [[PubMed](#)]
62. Gaziano, J.M. Should we fast before we measure our lipids? *Arch. Intern. Med.* **2012**, *172*, 1705–1706. [[CrossRef](#)] [[PubMed](#)]
63. Khera, A.V.; Mora, S. Fasting for lipid testing: Is it worth the trouble? *Arch. Intern. Med.* **2012**, *172*, 1710–1712. [[CrossRef](#)]
64. Sidhu, D.; Naugler, C. Fasting time and lipid levels in a community-based population: A cross-sectional study. *Arch. Intern. Med.* **2012**, *172*, 1707–1710. [[CrossRef](#)]
65. Nordestgaard, B.G.; Hilsted, L.; Stender, S. Plasma lipids in non-fasting patients and signal values of laboratory results. *Ugeskr. Laeger.* **2009**, *171*, 1093.
66. Langsted, A.; Nordestgaard, B.G. Nonfasting lipids, lipoproteins, and apolipoproteins in individuals with and without diabetes: 58,434 individuals from the Copenhagen General Population Study. *Clin. Chem.* **2011**, *57*, 482–489. [[CrossRef](#)]
67. National Clinical Guideline Centre (UK). Lipid Modification: Cardiovascular Risk Assessment and the Modification of Blood Lipids for the Primary and Secondary Prevention of Cardiovascular Disease. National Institute for Health and Care Excellence (UK); 2014. Available online: <http://www.ncbi.nlm.nih.gov/books/NBK248067/> (accessed on 2 September 2021).
68. Nordestgaard, B.G.; Langsted, A.; Mora, S.; Kolovou, G.; Baum, H.; Bruckert, E.; Watts, G.F.; Sypniewska, G.; Wiklund, O.; Borén, J.; et al. Fasting is not routinely required for determination of a lipid profile: Clinical and laboratory implications including flagging at desirable concentration cut-points—a joint consensus statement from the European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory Medicine. *Eur. Heart J.* **2016**, *37*, 1944–1958. [[CrossRef](#)] [[PubMed](#)]
69. Kim, J.; Staedelin, L.; Takser, L.; Abdelouahab, N.; Zhu, J. Assessment of selected chlorinated and brominated flame retardants in human plasma samples among co-residing family members. *Environ. Pollut.* **2019**, *252*, 1035–1041. [[CrossRef](#)]
70. Laue, H.E.; Cassoulet, R.; Abdelouahab, N.; Serme-Gbedo, Y.K.; Desautels, A.S.; Brennan, K.J.M.; Bellenger, J.-P.; Burriss, H.H.; Coull, B.A.; Weisskopf, M.G.; et al. Association between Meconium Acetaminophen and Childhood Neurocognitive Development in GESTE, a Canadian Cohort Study. *Toxicol. Sci.* **2019**, *167*, 138–144. [[CrossRef](#)]
71. Harris, P.A.; Taylor, R.; Thielke, R.; Payne, J.; Gonzalez, N.; Conde, J.G. Research electronic data capture (REDCap)—A metadata-driven methodology and workflow process for providing translational research informatics support. *J. Biomed. Inform.* **2009**, *42*, 377–381. [[CrossRef](#)]
72. Covaci, A.; Voorspoels, S. Optimization of the determination of polybrominated diphenyl ethers in human serum using solid-phase extraction and gas chromatography-electron capture negative ionization mass spectrometry. *J. Chromatogr. B Analyt. Technol. Biomed. Life Sci.* **2005**, *827*, 216–223. [[CrossRef](#)]
73. Friedewald, W.T.; Levy, R.I.; Fredrickson, D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. *Clin. Chem.* **1972**, *18*, 499–502. [[CrossRef](#)]
74. Phillips, D.L.; Pirkle, J.L.; Burse, V.W.; Bernert, J.T., Jr.; Henderson, L.O.; Needham, L.L. Chlorinated hydrocarbon levels in human serum: Effects of fasting and feeding. *Arch. Environ. Contam. Toxicol.* **1989**, *18*, 495–500. [[CrossRef](#)]
75. Bergonzi, R.; De Palma, G.; Tomasi, C.; Ricossa, M.C.; Apostoli, P. Evaluation of different methods to determine total serum lipids for normalization of circulating organochlorine compounds. *Int. Arch. Occup. Environ. Health* **2009**, *82*, 1241–1247. [[CrossRef](#)] [[PubMed](#)]
76. Planchart, A.; Green, A.; Hoyo, C.; Mattingly, C.J. Heavy Metal Exposure and Metabolic Syndrome: Evidence from Human and Model System Studies. *Curr. Environ. Health Rep.* **2018**, *5*, 110–124. [[CrossRef](#)] [[PubMed](#)]
77. Iglewicz, B.; Hoaglin, D. Volume 16, How to Detect and Handle Outliers. In *The ASQC Basic References in Quality Control. Statistical Techniques*; Mykytka, E.F., Ed.; ASQC Quality Press: Milwaukee, WI, USA, 1993; pp. 1–85.